CADL Valuation

Candel Therapeutics Inc

Add to Watchlist

Advanced Chart

7.000

+0.04(0.575%)1D

Overview
Forecast
Valuation
Earnings

CADL Relative Valuation

CADL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CADL is overvalued; if below, it's undervalued.

Historical Valuation

Candel Therapeutics Inc (CADL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.86. The fair price of Candel Therapeutics Inc (CADL) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：7.00

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.59

P/B

Median3y

0.49

Median5y

0.83

-8.14

FCF Yield

Median3y

-51.01

Median5y

-42.09

Competitors Valuation Multiple

The average P/S ratio for CADL's competitors is 23.02, providing a benchmark for relative valuation. Candel Therapeutics Inc Corp (CADL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CADL.O

Candel Therapeutics Inc

Loss

Average P/S: 23.02

367.28M